Status:
COMPLETED
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
Lead Sponsor:
Pfizer
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
To determine if the NMDA antagonist, CP-101,606, is effective for depression
Eligibility Criteria
Inclusion
- Primary DSM-IV diagnosis of MDD
Exclusion
- Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00163059
Start Date
May 1 2004
End Date
December 1 2005
Last Update
September 22 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Wichita, Kansas, United States, 67214-2878